Aspire Biopharma shares surge 12.55% intraday after subsidiary signs TruLife distribution deal to expand BUZZ BOMB™ retail footprint.

Aspire Biopharma surged 12.55% intraday following the announcement that its subsidiary, Buzz Bomb Caffeine Company, entered a partnership with TruLife Distribution to expand the national retail distribution of BUZZ BOMB™ caffeine products. The agreement targets natural, organic, specialty, and mass-merchandiser channels, aiming to enhance the brand’s retail footprint through TruLife’s expertise in scaling health and wellness brands. BUZZ BOMB’s innovative dry-powder caffeine delivery system, positioned as a convenient alternative to liquid energy drinks, is expected to capitalize on growing demand for functional on-the-go energy solutions. Executives from both companies emphasized the strategic value of the partnership, with Aspire’s interim CEO noting the energy segment’s growth potential and TruLife’s CEO highlighting the product’s differentiation in a competitive market. The news directly aligns with the stock’s sharp intraday rally, underscoring investor optimism about expanded market access and revenue opportunities.